Hamza Suria
Chief Executive Officer chez Trotana, Inc.
Fortune : - $ au 31/03/2024
Profil
Hamza Suria is the CEO of Trotana, Inc. He previously worked as the President, CEO, and Director of AnaptysBio, Inc. from 2011 to 2022.
Prior to that, he held senior positions in business development at Maxygen, Inc., Diabetogen Biosciences, Inc., and Viron Therapeutics, Inc. Suria received his undergraduate degree from Kalamazoo College and attended Mercersburg Academy.
He also received a graduate degree from the University of Western Ontario and an MBA from the Richard Ivey School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANAPTYSBIO, INC.
-.--% | 24/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Hamza Suria
| Sociétés | Poste | Début |
|---|---|---|
Trotana, Inc.
 Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Chief Executive Officer | - |
Anciens postes connus de Hamza Suria
| Sociétés | Poste | Fin |
|---|---|---|
| ANAPTYSBIO, INC. | Chief Executive Officer | 20/03/2022 |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Corporate Officer/Principal | - |
| Diabetogen Biosciences, Inc. | Corporate Officer/Principal | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Formation de Hamza Suria
| Kalamazoo College | Undergraduate Degree |
| University of Western Ontario | Graduate Degree |
| Mercersburg Academy | Undergraduate Degree |
| Richard Ivey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ANAPTYSBIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
| Diabetogen Biosciences, Inc. | |
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Health Technology |
